Market Cap 371.87M
Revenue (ttm) 114.20M
Net Income (ttm) 120,000.00
EPS (ttm) N/A
PE Ratio 2.15
Forward PE N/A
Profit Margin 0.11%
Debt to Equity Ratio -0.15
Volume 1,575,800
Avg Vol 5,096,772
Day's Range N/A - N/A
Shares Out 45.02M
Stochastic %K 48%
Beta 1.41
Analysts Strong Sell
Price Target $15.67

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGE...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
A_I_R_IKAZEE
A_I_R_IKAZEE Aug. 20 at 7:50 PM
$AGEN https://x.com/adamfeuerstein/status/2090475950576205842?s=12&t=YI1KI5hF_qb5_PH7hWarpg
0 · Reply
MGroup
MGroup Aug. 20 at 7:19 PM
$SLS $AGEN and $IOVA all short squeeze candidates IMO.
0 · Reply
NYBomba
NYBomba Aug. 20 at 7:10 PM
$AGEN - bottom-line, Healthcare sector is beet red today, que-sera-sera
0 · Reply
Dazedconfused12
Dazedconfused12 Aug. 20 at 7:05 PM
$AGEN how much more betrayal can I take
0 · Reply
joechuck71
joechuck71 Aug. 20 at 7:02 PM
$AGEN what a buy here.
0 · Reply
NYBomba
NYBomba Aug. 20 at 7:02 PM
$AGEN - in just 6 weeks we're up over 100 percent, you don't say .... today's volume is just 25 percent of the average volume, why do you think that is? Can't take daily stock price movement, invest in a CD ... no place for cry babies ...
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Aug. 20 at 6:22 PM
$AGEN so we’re down the same amount we went up? You don’t say….
0 · Reply
ggoose18
ggoose18 Aug. 20 at 5:30 PM
$AGEN I bought MRNA at $118 yesterday morning and sold at 165 last night. Guess I should have sold some of this as well. Not sure with I don’t,
1 · Reply
neversurrender2024
neversurrender2024 Aug. 20 at 4:21 PM
$AGEN took it all back and then some.....lol
0 · Reply
Jcilip01
Jcilip01 Aug. 20 at 4:08 PM
$AGEN Is the FDA BIASED. Based on the following data, I would say YES!! Nearly 45% of the FDA's total budget is funded by industry "user fees" rather than direct corporate donations or general taxpayer money. Major pharmaceutical companies—such as Pfizer, Novartis, AstraZeneca, Merck & Co., and Eli Lilly—pay these mandated fees. How the Funding Works Prescription Drug User Fee Act (PDUFA): Enacted in 1992, PDUFA requires drugmakers to pay fees for submitting new drug applications and maintaining commercial product lines. Scope of Contributors: Virtually every large, mid-size, and generic pharmaceutical or medical device manufacturer seeking market approval from the FDA contributes through these mandatory fee schedules. Purpose and Quid Pro Quo: The fees pay for the scientific and regulatory staff needed to review drug applications. In exchange, the FDA commits to meeting specific review-time performance goals.
2 · Reply
Latest News on AGEN
Agenus Registration statement: Registration filing

Aug 7, 2026, 8:00 AM EDT - 13 days ago

Agenus Registration statement: Registration filing


Agenus Earnings release: Q2 2026

Aug 6, 2026, 9:30 AM EDT - 14 days ago

Agenus Earnings release: Q2 2026


Agenus Quarterly report: Q2 2026

Aug 6, 2026, 9:30 AM EDT - 14 days ago

Agenus Quarterly report: Q2 2026


Agenus reports Q2 revenue $34.5M vs $25.7M last year

2026-08-06T11:52:23.000Z - 14 days ago

Agenus reports Q2 revenue $34.5M vs $25.7M last year


Agenus Slides: Corporate presentation

Jul 30, 2026, 9:00 AM EDT - 21 days ago

Agenus Slides: Corporate presentation


Agenus price target raised to $14 from $8 at B. Riley

2026-07-30T12:37:16.000Z - 21 days ago

Agenus price target raised to $14 from $8 at B. Riley


Agenus Registration statement: Registration filing

Jul 20, 2026, 8:00 AM EDT - 4 weeks ago

Agenus Registration statement: Registration filing


Agenus files to sell 2.13M shares of common stock for holders

2026-07-20T10:10:56.000Z - 4 weeks ago

Agenus files to sell 2.13M shares of common stock for holders


Why Is Agenus (AGEN) Stock Up Today?

2026-07-13T16:51:30.000Z - 5 weeks ago

Why Is Agenus (AGEN) Stock Up Today?


Agenus price target raised to $30 from $23 at H.C. Wainwright

2026-07-13T16:20:13.000Z - 5 weeks ago

Agenus price target raised to $30 from $23 at H.C. Wainwright


Agenus Transcript: Investor update

Jul 13, 2026, 8:30 AM EDT - 5 weeks ago

Agenus Transcript: Investor update


Agenus Press release: Investor update

Jul 13, 2026, 8:30 AM EDT - 5 weeks ago

Agenus Press release: Investor update


Agenus Slides: Investor update

Jul 13, 2026, 8:30 AM EDT - 5 weeks ago

Agenus Slides: Investor update


Agenus announces $340M private placement

2026-07-13T10:05:12.000Z - 5 weeks ago

Agenus announces $340M private placement

LGND


Agenus reports three-year Phase 1b BOT+BAL data at ESMO GI

2026-07-06T11:35:16.000Z - 6 weeks ago

Agenus reports three-year Phase 1b BOT+BAL data at ESMO GI


Agenus Transcript: AGM 2026

Jun 16, 2026, 10:00 AM EDT - 2 months ago

Agenus Transcript: AGM 2026


Agenus Announces Virtual 2026 Annual Shareholders Meeting

Jun 2, 2026, 4:30 PM EDT - 2 months ago

Agenus Announces Virtual 2026 Annual Shareholders Meeting


Agenus announces publication of Phase 1b BOT+BAL data

2026-05-15T20:23:26.000Z - 3 months ago

Agenus announces publication of Phase 1b BOT+BAL data


Agenus Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 3 months ago

Agenus Proxy statement: Proxy filing


Agenus reports Q1 revenue $33.7M vs. $24.1M last year

2026-05-11T14:42:15.000Z - 3 months ago

Agenus reports Q1 revenue $33.7M vs. $24.1M last year


Agenus provides 2026 strategic priorities

2026-05-11T14:38:34.000Z - 3 months ago

Agenus provides 2026 strategic priorities


Agenus Earnings release: Q1 2026

May 11, 2026, 9:30 AM EDT - 3 months ago

Agenus Earnings release: Q1 2026


Agenus Quarterly report: Q1 2026

May 11, 2026, 9:30 AM EDT - 3 months ago

Agenus Quarterly report: Q1 2026


Agenus Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Agenus Proxy statement: Proxy filing


Agenus Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Agenus Proxy statement: Proxy filing


Agenus Transcript: AGM 2026

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Agenus Transcript: AGM 2026


Agenus Annual report: Q4 2025

Mar 16, 2026, 9:30 AM EDT - 5 months ago

Agenus Annual report: Q4 2025


Agenus Earnings release: Q4 2025

Mar 16, 2026, 9:30 AM EDT - 5 months ago

Agenus Earnings release: Q4 2025


Agenus Transcript: Status update

Jan 28, 2026, 4:00 PM EST - 7 months ago

Agenus Transcript: Status update


Agenus to Host First 2026 Stakeholder Webcast

Jan 20, 2026, 6:24 PM EST - 7 months ago

Agenus to Host First 2026 Stakeholder Webcast


Agenus Quarterly report: Q3 2025

Nov 10, 2025, 9:30 AM EST - 10 months ago

Agenus Quarterly report: Q3 2025


Agenus Earnings release: Q3 2025

Nov 10, 2025, 9:30 AM EST - 10 months ago

Agenus Earnings release: Q3 2025


Agenus Transcript: Status Update

Oct 21, 2025, 4:00 PM EDT - 10 months ago

Agenus Transcript: Status Update


Agenus Slides: Corporate Presentation

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Agenus Slides: Corporate Presentation


Agenus Transcript: Stakeholder Briefing

Aug 27, 2025, 4:00 PM EDT - 1 year ago

Agenus Transcript: Stakeholder Briefing


Agenus Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Agenus Earnings Call Transcript: Q2 2025


Agenus Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Agenus Quarterly report: Q2 2025


Agenus Earnings release: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Agenus Earnings release: Q2 2025


Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 1 year ago

Agenus Announces Virtual Annual Shareholders Meeting


Agenus Proxy statement: Proxy Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing


Agenus Transcript: Collaboration

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Transcript: Collaboration


Agenus Press release: Collaboration

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Press release: Collaboration


Agenus Earnings Call Transcript: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings Call Transcript: Q1 2025


Agenus Quarterly report: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Quarterly report: Q1 2025


Agenus Earnings release: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings release: Q1 2025


Agenus Registration statement: Registration Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Agenus Registration statement: Registration Filing


A_I_R_IKAZEE
A_I_R_IKAZEE Aug. 20 at 7:50 PM
$AGEN https://x.com/adamfeuerstein/status/2090475950576205842?s=12&t=YI1KI5hF_qb5_PH7hWarpg
0 · Reply
MGroup
MGroup Aug. 20 at 7:19 PM
$SLS $AGEN and $IOVA all short squeeze candidates IMO.
0 · Reply
NYBomba
NYBomba Aug. 20 at 7:10 PM
$AGEN - bottom-line, Healthcare sector is beet red today, que-sera-sera
0 · Reply
Dazedconfused12
Dazedconfused12 Aug. 20 at 7:05 PM
$AGEN how much more betrayal can I take
0 · Reply
joechuck71
joechuck71 Aug. 20 at 7:02 PM
$AGEN what a buy here.
0 · Reply
NYBomba
NYBomba Aug. 20 at 7:02 PM
$AGEN - in just 6 weeks we're up over 100 percent, you don't say .... today's volume is just 25 percent of the average volume, why do you think that is? Can't take daily stock price movement, invest in a CD ... no place for cry babies ...
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Aug. 20 at 6:22 PM
$AGEN so we’re down the same amount we went up? You don’t say….
0 · Reply
ggoose18
ggoose18 Aug. 20 at 5:30 PM
$AGEN I bought MRNA at $118 yesterday morning and sold at 165 last night. Guess I should have sold some of this as well. Not sure with I don’t,
1 · Reply
neversurrender2024
neversurrender2024 Aug. 20 at 4:21 PM
$AGEN took it all back and then some.....lol
0 · Reply
Jcilip01
Jcilip01 Aug. 20 at 4:08 PM
$AGEN Is the FDA BIASED. Based on the following data, I would say YES!! Nearly 45% of the FDA's total budget is funded by industry "user fees" rather than direct corporate donations or general taxpayer money. Major pharmaceutical companies—such as Pfizer, Novartis, AstraZeneca, Merck & Co., and Eli Lilly—pay these mandated fees. How the Funding Works Prescription Drug User Fee Act (PDUFA): Enacted in 1992, PDUFA requires drugmakers to pay fees for submitting new drug applications and maintaining commercial product lines. Scope of Contributors: Virtually every large, mid-size, and generic pharmaceutical or medical device manufacturer seeking market approval from the FDA contributes through these mandatory fee schedules. Purpose and Quid Pro Quo: The fees pay for the scientific and regulatory staff needed to review drug applications. In exchange, the FDA commits to meeting specific review-time performance goals.
2 · Reply
BakerBrother
BakerBrother Aug. 20 at 3:27 PM
$AGEN let’s say we can recruit 60 patients a month (similar to BATTMAN) and we begin recruiting April 2027. I feel like we knew pretty quickly (within months) that NEST-1 and NEST-2 were breakthroughs. Obviously it takes two years to get to two years though. How many responses do we need to show statistical significance and over what time period? This is just trying to think about how soon we could get an efficacy signal. Thanks.
4 · Reply
Brunoez
Brunoez Aug. 20 at 3:16 PM
$AGEN bigred--The reality is that there is nothing special about cancer research stocks from the point of view of large investors. Nor should there be. In fact, short investors provide a necessary element to the stock market as a whole by exposing fraud and inefficiency. The bottom line is that the performance of this stock has nothing to do with shorts (I'm not one of them). The new funding is great news, but scrapping the BATTMAN trial set everything back another few years.
2 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Aug. 20 at 3:01 PM
$AGEN yesterday was just riding in Moderna coat tails
2 · Reply
neversurrender2024
neversurrender2024 Aug. 20 at 2:45 PM
$AGEN theyre not shorting cancer research, thyre shorting incompetence and the last 5 years shows how much incompetence exists in this greedy management team....lol
0 · Reply
bigred1414
bigred1414 Aug. 20 at 2:01 PM
$AGEN tomorrow is expiration for options. Shorts trying to move SP down to save their ass? Sleezebags! If their family gets cancer, they can tell them they shorted cancer research stocks!
1 · Reply
neversurrender2024
neversurrender2024 Aug. 20 at 1:46 PM
$AGEN good call !
0 · Reply
joechuck71
joechuck71 Aug. 20 at 12:04 PM
$AGEN "My" Bet is Dr Garo is inline with investors and will get paid stock options on proformance "if" i am correct his first payday is $23 if he wanted to exercise his options at the trench leavel . 0 sec 4 filings as 2 -logs-higher has shown us every few weeks 0 stock pays in 6 weeks very large stock options given to Dr Garo and this is not norm so i would love to see the 8k on this, the stock would fill the 14 gap in 10 min. Also the stocks moving up maybe i am correct maybe
0 · Reply
Stefman9
Stefman9 Aug. 20 at 11:07 AM
0 · Reply
Dazedconfused12
Dazedconfused12 Aug. 20 at 2:27 AM
$AGEN wish I had more then 1500 shares
1 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Aug. 20 at 1:27 AM
$AGEN https://x.com/moontrades7/status/2090079590660075988?s=12&t=YI1KI5hF_qb5_PH7hWarpg
0 · Reply
CapitalMonk
CapitalMonk Aug. 19 at 10:32 PM
$AGEN Price: $8.26 (+9.69%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.43% RSI: 53.9 | Momentum: Moderate Volume: +37.5% vs avg Volatility: 6.64% Support: $5.46 | Resistance: $8.85 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Aug. 19 at 10:08 PM
$AGEN any guesses on robbins halted for efficacy date?
2 · Reply